Incubate has urged Congress to take action and ensure the 2025 Special 301 Report  reaffirms America’s commitment to safeguarding...

Read Incubate's blog on the recently announced March-In proposal. Incubate recently submitted a comment letter intended to educate...

An Open Letter to Members of Congress and the Biden Administration from Leaders in the Life Sciences Community As leaders... An Open...

Incubate and DLA Piper hosted a breakfast panel at this year's J.P. Morgan Healthcare Conference in San Francisco, California. Incubate...

After a nine-month review, the Biden administration has reached the unprecedented and misguided conclusion that the 1980 Bayh-Dole Act...

In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting...

The small-molecule penalty "doesn't create the right incentives for where we want to go with the Cancer Moonshot or driving cures," Mohit...

Executive Director John Stanford testified before the International Trade Organization.

The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written...